Article Sidebar
Published:
Oct 13, 2022DOI:
10.4314/tjpr.v21i9.2Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Berberine regulates endocrine function in mice with polycystic ovary syndrome through PI3K/Akt/GSK-3β insulin signaling pathway
Abstract
Purpose: To study the influence of berberine on endocrine status in mice with polycystic ovary syndrome (PCOS), and the underlying mechanism of action.
Methods: A total of 80 mice were used in this research. Sixteen mice were randomly selected to serve as control. The remaining 64 mice were subcutaneously given dehydroepiandrosterone (DHEA) injection to establish a mouse model of PCOS. The PCOS mice were randomly divided into model group, and low-dose-, medium-dose and high-dose berberine groups. Oral glucose tolerance test (OGTT) and expression levels of PI3K/Akt/GSK-3 signaling pathway related proteins (PI3K 85, Akt2, p-GSK-3 Tyr216, p-GSK-3β Ser9, and GSK-3) were evaluated.
Results: At 60 and 120 min, OGTT blood glucose level of model group was significantly higher than that of blank control group, but it was significantly lower in the berberine dose groups than in model group (p < 0.05). There were significantly higher protein expression levels of pi3k85, AKT2 and p-GSK-3β tyr116 in berberine dose groups than in model mice, but the protein levels of p-GSK-3β ser9 in berberine dose groups were significantly lower than that in model mice.
Conclusion: Berberine improved endocrine function in PCOS mice through a mechanism involving regulation of the key proteins of PI3K/Akt/GSK-3 β insulin signaling pathway. Thus, berberine may potentially play a similar role in humans with PCOS functions. However, clinical trials need to be carried out first.
